<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328548</url>
  </required_header>
  <id_info>
    <org_study_id>09-450</org_study_id>
    <nct_id>NCT01328548</nct_id>
  </id_info>
  <brief_title>Zoster Vaccine Response in the Frail Elderly</brief_title>
  <official_title>Immune and Genetic Correlates of Response to Zoster Vaccine in the Frail Elderly: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the zoster vaccine response in the nursing home elderly
      (80 years or older). As the immune system ages, the response to vaccines is not always as
      strong as in younger people. Previous zoster vaccine studies have excluded nursing home
      residents so the vaccine effect in this population is not known. Furthermore, the immune and
      genetic reasons as to why the vaccine works well in some people but not in others are also
      unknown. The goal of this study is to evaluate why some immune systems respond well to the
      vaccine and why others do not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deleterious changes in immunity that occur with aging are known as immunosenescence. Such
      changes, particularly in adaptive immunity, may lead to an impaired vaccine response in the
      elderly. Characterizing the immune determinants and the genetic basis for vaccine response
      in the frail elderly is a practical approach to better our understanding of
      immunosenescence. Data on genetic determinants to immunization are sparse, furthermore, to
      the best of our knowledge, none exist in the elderly. In this pilot study, we propose
      studying the immune response to the herpes zoster vaccine and the underlying genetic
      determinants of the immune response in elderly residents of nursing homes.

      The three specific aims of this study are to generate data in order to 1) assess the T-cell
      response to the varicella-zoster virus (VZV) vaccine in the frail elderly; 2) assess whether
      immune (T-cell) phenotypes are associated with a response; 3) test the association between
      immune response genotype sets and T-cell response. We hypothesize that response to the VZV
      vaccine in elderly nonambulatory nursing home residents is a function of characteristic
      T-cell immune phenotypes prior to vaccination and that there are immune genetic
      polymorphisms associated with the response. This study will allow us to generate preliminary
      data and establish feasibility in order to address these questions fully in a larger
      population in a subsequent grant application.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in T-cell response to the VZV vaccine in the frail elderly</measure>
    <time_frame>6 weeks</time_frame>
    <description>As the primary phenotype, we will compare change in responder cell frequency (RCF) and Enzyme-linked immunosorbent spot (ELISPOT) from baseline (i.e., pre and post vaccination). A high baseline T cell response will be defined as RCF = &gt;5.0 and ELISPOT = &gt;50 spots and a low baseline response will be RCF = &lt;1.0 and ELISPOT = &lt;10 spots.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of immune parameters compatible with inflammaging: CD4+/CD8+ ratio</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in each participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of immune parameters compatible with inflammaging: high CD8+CD28-CD45RA+ T cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in each participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of immune parameters compatible with inflammaging: TEMRA Cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in each participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of immune parameters compatible with inflammaging: high T regulatory cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in each participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Testing 150 candidate immune response genes for SNP analysis</measure>
    <time_frame>Baseline</time_frame>
    <description>These will include Toll-like receptors, cytokines, chemokines, chemokine receptors, interferons and interferon receptors.
Toll-like receptors: TLR1-TLR9 Cytokines: ILI1A, ILI1B, IL1RN, IL4, IL5, IL12B, IL13, CSF2 Chemokines: CCL1-CCL3, CCL3L1, CCL4-CCL8, CCL11, CCL13, CCL15-CCL28, CXCL1-CXCL14, CXCL16, CX3CL1 Chemokine receptors: CCR1-CCR10, CXCR1-CXCR6, CX3CR1, XCR1-XCR2 Interferons: IFNA1-IFNA2, IFNA4-IFNA8, IFNA10, IFNA13, IFNA14, IFNA16-IFNA17, IFNA21, IFNB1, IFNB3, IFNG, IFNK, IFNW1 Interferon receptors: IFNAR1, IFNAR2, IFNGR1, IFNGR2</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>Nursing Home Elderly Cases</arm_group_label>
    <description>Non-ambulatory nursing home residents &lt;= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A case will be considered failure to mount a high response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nursing Home Elderly Controls</arm_group_label>
    <description>Non-ambulatory nursing home residents &lt;= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Community dwelling seniors</arm_group_label>
    <description>Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Retained specimens include DNA and blood cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly, non-ambulatory residents of nursing homes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nursing home resident

          -  greater than or equal to 80 years old

          -  non-ambulatory

        Exclusion Criteria:

          -  less than 80 years old

          -  ambulatory

          -  taking immunosuppressive medication

          -  history of primary or acquired immuno-deficiency states including leukemia, other
             malignant neoplasms affecting the bone marrow or lymphatic system, and AIDS

          -  active untreated tuberculosis

          -  previous receipt of varicella vaccine

          -  residents expected to expire within 30 days, in the opinion of the most responsible
             physician

          -  residents planning to move nursing homes within the year

          -  temporary residents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark B. Loeb, FRCPC,MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Macassa Lodge</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa K, Pawelec G. Dysregulation of T-cell function in the elderly : scientific basis and clinical implications. Drugs Aging. 2005;22(7):589-603. Review.</citation>
    <PMID>16038574</PMID>
  </reference>
  <reference>
    <citation>Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006 Mar;127(3):274-81. Epub 2005 Dec 13.</citation>
    <PMID>16352331</PMID>
  </reference>
  <reference>
    <citation>Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev. 2007 Dec;65(12 Pt 2):S173-6. Review.</citation>
    <PMID>18240544</PMID>
  </reference>
  <reference>
    <citation>Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis. 2006 Mar 1;193(5):655-63. Epub 2006 Jan 27.</citation>
    <PMID>16453260</PMID>
  </reference>
  <reference>
    <citation>Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology. 2005 Jun;41(6):1383-90.</citation>
    <PMID>15915462</PMID>
  </reference>
  <reference>
    <citation>Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004 Apr;39(4):978-88.</citation>
    <PMID>15057902</PMID>
  </reference>
  <reference>
    <citation>Gelder CM, Lambkin R, Hart KW, Fleming D, Williams OM, Bunce M, Welsh KI, Marshall SE, Oxford J. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis. 2002 Jan 1;185(1):114-7. Epub 2001 Dec 14.</citation>
    <PMID>11756990</PMID>
  </reference>
  <reference>
    <citation>Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002 Aug 1;347(5):340-6. Review.</citation>
    <PMID>12151472</PMID>
  </reference>
  <reference>
    <citation>Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983 Dec 8;309(23):1434-40. Review.</citation>
    <PMID>6195526</PMID>
  </reference>
  <reference>
    <citation>Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella zoster virus: virology and clinical management. Cambridge, England: Cambridge University Press, 2000:246-75.</citation>
  </reference>
  <reference>
    <citation>BURGOON CF Jr, BURGOON JS, BALDRIDGE GD. The natural history of herpes zoster. J Am Med Assoc. 1957 May 18;164(3):265-9.</citation>
    <PMID>13415974</PMID>
  </reference>
  <reference>
    <citation>Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982 Sep;61(5):310-6.</citation>
    <PMID>6981045</PMID>
  </reference>
  <reference>
    <citation>Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995 Aug 7-21;155(15):1605-9.</citation>
    <PMID>7618983</PMID>
  </reference>
  <reference>
    <citation>Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996 Oct;67(2-3):241-51. Review.</citation>
    <PMID>8951917</PMID>
  </reference>
  <reference>
    <citation>Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology. 1995 Dec;45(12 Suppl 8):S52-3.</citation>
    <PMID>8545021</PMID>
  </reference>
  <reference>
    <citation>Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975 Aug;25(157):571-5.</citation>
    <PMID>1195231</PMID>
  </reference>
  <reference>
    <citation>Kost RG, Straus SE. Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med. 1996 Jul 4;335(1):32-42. Review.</citation>
    <PMID>8637540</PMID>
  </reference>
  <reference>
    <citation>Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun. 1981 Apr;32(1):24-7.</citation>
    <PMID>6163722</PMID>
  </reference>
  <reference>
    <citation>Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982 Feb;142(2):291-3.</citation>
    <PMID>6277260</PMID>
  </reference>
  <reference>
    <citation>Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992 Aug;166(2):253-9.</citation>
    <PMID>1321859</PMID>
  </reference>
  <reference>
    <citation>Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.</citation>
    <PMID>18419349</PMID>
  </reference>
  <reference>
    <citation>Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group.. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84.</citation>
    <PMID>15930418</PMID>
  </reference>
  <reference>
    <citation>Levin MJ. Herpes zoster vaccine. In: Plotkin SA, ed. Vaccines— Continuing Medical Education Update. Bridgewater (NJ): Elsevier Office of CME, January 2007 pp. 1-10.</citation>
  </reference>
  <reference>
    <citation>Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.</citation>
    <PMID>17443464</PMID>
  </reference>
  <reference>
    <citation>Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006 Nov 1;43(9):1143-51. Epub 2006 Oct 2.</citation>
    <PMID>17029132</PMID>
  </reference>
  <reference>
    <citation>Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, Wikby A, Strindhall J, Franceschi C, Pawelec G. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci. 2007 Oct;1114:23-35. Review.</citation>
    <PMID>17986574</PMID>
  </reference>
  <reference>
    <citation>Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol. 2009 Jan;19(1):47-56. doi: 10.1002/rmv.598. Review.</citation>
    <PMID>19035529</PMID>
  </reference>
  <reference>
    <citation>Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, thor Straten P, Wikby A. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006 Feb 15;176(4):2645-53.</citation>
    <PMID>16456027</PMID>
  </reference>
  <reference>
    <citation>Pawelec G, Sansom D, Rehbein A, Adibzadeh M, Beckman I. Decreased proliferative capacity and increased susceptibility to activation-induced cell death in late-passage human CD4+ TCR2+ cultured T cell clones. Exp Gerontol. 1996 Nov-Dec;31(6):655-68.</citation>
    <PMID>9415095</PMID>
  </reference>
  <reference>
    <citation>Spaulding C, Guo W, Effros RB. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol. 1999 Aug;34(5):633-44.</citation>
    <PMID>10530789</PMID>
  </reference>
  <reference>
    <citation>Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci. 1995 Nov;50(6):B378-82.</citation>
    <PMID>7583794</PMID>
  </reference>
  <reference>
    <citation>Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev. 1998 May 15;102(2-3):187-98.</citation>
    <PMID>9720651</PMID>
  </reference>
  <reference>
    <citation>Kostyu DD, Ober CL, Dawson DV, Ghanayem M, Elias S, Martin AO. Genetic analysis of HLA in the U.S. Schmiedenleut Hutterites. Am J Hum Genet. 1989 Aug;45(2):261-9.</citation>
    <PMID>2757031</PMID>
  </reference>
  <reference>
    <citation>Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95.</citation>
    <PMID>16129869</PMID>
  </reference>
  <reference>
    <citation>Rockwood K, Abeysundera MJ, Mitnitski A. How should we grade frailty in nursing home patients? J Am Med Dir Assoc. 2007 Nov;8(9):595-603. Epub 2007 Oct 22.</citation>
    <PMID>17998116</PMID>
  </reference>
  <reference>
    <citation>Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):722-7. Review.</citation>
    <PMID>17634318</PMID>
  </reference>
  <reference>
    <citation>Bell PA, Chaturvedi S, Gelfand CA, Huang CY, Kochersperger M, Kopla R, Modica F, Pohl M, Varde S, Zhao R, Zhao X, Boyce-Jacino MT, Yassen A. SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques. 2002 Jun;Suppl:70-2, 74, 76-7. Erratum in: Biotechniques. 2003 Mar;34(3):496.</citation>
    <PMID>12083401</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 12, 2015</lastchanged_date>
  <firstreceived_date>March 15, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Mark Loeb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>varicella-zoster virus</keyword>
  <keyword>vaccine</keyword>
  <keyword>T-cell</keyword>
  <keyword>genes</keyword>
  <keyword>frail elderly</keyword>
  <keyword>immunosenescence</keyword>
  <keyword>immune and genetic correlates of response to zoster vaccine in the elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
